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Abstract
Background: Debate on the optimal mode of preoperative imaging in the management of colorectal
liver metastases (CRLM) is ongoing and, despite its longstanding use, the precise role of intraoperative
ultrasonography (IOUS) is not well established. This study evaluates the impact of IOUS in the era of
high-quality, cross-sectional imaging techniques.
Methods: All patients who underwent liver resection for CRLM in a tertiary care referral centre from
January 2006 to December 2013 were included. All patients were submitted to computed tomography
(CT) and/or liver magnetic resonance imaging (MRI) before surgery. Intraoperative US was performed
mainly to detect previously non-diagnosed tumours that would change the surgical strategy.
Results: A total of 225 liver resections were performed. Liver MRI and CT scans were available for
202 patients (89.8%) and 225 patients (100%), respectively. Radiological reports recorded 632 liver
tumours in 219 patients (i.e. 2.9 lesions per patient). The median time between preoperative liver MRI
and surgical resection was 36 days. Intraoperative inspection, palpation and US found 20 additional
lesions in 18 patients (8.0%), in three of whom lesions were diagnosed only on IOUS (1.4%). Overall,
only 12 of the 20 lesions were malignant.
Conclusions: Although CT and liver MRI are commonly used, IOUS alone allows the discovery of a
few additional lesions that result in a change of surgical strategy in 1.4% of cases.
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Introduction
Over 42 000 cases of colorectal cancer are diagnosed every
year in France. The disease is one of the most common
causes of cancer-related death and involves the second most
frequent location of cancer in both sexes.1 Liver metastases
from colorectal primary tumours are observed at diagnosis in
20% of patients2 and in 50–75% of patients within 3 years.3,4
The liver is the most common site of colorectal cancer metas-
tasis, the occurrence of which represents the most critical prog-
nostic factor as colorectal liver metastases (CRLM) are the main
cause of mortality in two-thirds of cases.5 Margin-free (R0)
surgical resection is the goal and leads to 5-year survival rates of
around 40% and 10-year survival rates can reach 25%, with low
mortality (<1%) and morbidity (20–40%) rates in high-volume
centres.6–9
Intraoperative ultrasonography (IOUS) is widely used by
surgeons, but its results are conflicting. Systematic IOUS liver
examination has been shown to yield significant new informa-
tion and may identify at least one additional lesion not seen
on preoperative imaging in 10–26% of patients and change the
surgical strategy in up to 72% of patients.5,10–12 However, in
most of the series reported to date, preoperative assessment is
variable and does not include systematic preoperative com-
puted tomography (CT) or liver magnetic resonance imaging
(MRI).
Liver MRI is used before surgery by some authors, who
argue that its sensitivity in the detection of liver metastases is
about 90%. Others advocate the use of preoperative fluorodes-
oxyglucose positron emission tomography (FDG-PET) or CT
screening before surgery.12,13
The present study was conducted to assess the role of IOUS in
the management of liver metastasis from colorectal cancer, in an
era marked by the frequent use of high-quality, cross-sectional
imaging techniques.
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Materials and methods
Study population
This single-centre study included all patients who underwent
liver resection for CRLM from January 2006 to December 2013
at Nancy-Brabois University Hospital.
Data were collected from the tertiary referral centre database.
Clinical, pathological and radiological parameters and out-
comes were analysed. These included age at diagnosis and at
surgery, gender, body mass index (BMI), American Society of
Anesthesiologists (ASA) score, primary tumour location and
the date of primary tumour resection. Data on any history of
preoperative or postoperative chemotherapy were also col-
lected. All radiology reports from liver MRI and CT scans were
reviewed. Intraoperative information, such as liver IOUS scan
details, type of resection and operative time, and postoperative
morbidity and mortality were recorded.
All patients had a histologically confirmed primary colorectal
cancer, resected or in place. Synchronous or metachronous
(i.e. >6 months after the identification of colorectal cancer)
liver metastases were diagnosed using CT and/or liver MRI
and/or FDG-PET.
All patients were discussed in a multidisciplinary team
(MDT) meeting, which included a radiologist specializing in
liver disease, hepatopancreatobiliary (HPB) surgeons and an
oncologist, to confirm the indications for surgery and/or chemo
therapy and/or radiotherapy.
Preoperative imaging
All patients underwent CT and/or liver MRI before surgery.
Scanning by FDG-PET was not routinely performed. Liver
MRI studies were carried out using a 1.5-T superconducting
system (Signa Excite HDx; General Electric Healthcare,
Milwaukee, WI, USA) with three axial sequences: fast spin
echo T2 (FSET2-1.5T); single-shot diffusion-weighted echo-
planar imaging (DWI-1.5T), and an in- and out-of- phase T1
weighted sequence. Three-dimensional liver acquisition with
volume acceleration sequences (LAVA) after gadoteric acid
injection (Dotarem; Laboratoire Guerbet, Aulnay-sous-Bois,
France) were also performed.
Intraoperative staging
Abdominal exploration was achieved first by visual inspection
and bimanual palpation, except in the laparoscopy group.
The liver was fully mobilized to facilitate US exploration of
the organ. Intraoperative US was performed by an experi-
enced hepatobiliary surgeon (AA, LBre) or by an experienced
radiologist (VC-L). Intraoperative US was performed to
detect previously non-diagnosed tumours that would change
the surgical strategy, and also to guide liver resection by
localizing the Glissonian structures and hepatic veins. Intra-
operative US did not focus on liver parenchyma that was
scheduled for resection, but concentrated only on the
intended residual liver. During these procedures, only new
lesions were counted; previously known lesions were not
systematically counted.
Follow-up
Postoperative treatments were assessed at the MDT meeting.
Thoracic and abdominal contrast-enhanced helical CT scans
were performed every 3 months for 2 years. This work-up was
complemented with liver MRI if necessary.
Data analysis
Statistical analysis was performed using R for Windows
Version 3.0.2 (R Foundation for Statistical Computing, Vienna,
Austria). Results were expressed as either the median (range)
or the mean  standard deviation (SD). Differences in means
between groups were compared using the Wilcoxon test. Com-
parisons between categorical variables were analysed using
Fisher’s exact test. P-values of <0.05 were considered to indi-
cate statistical significance.
Results
Demographic and clinical characteristics
A total of 225 liver resections were performed during the study
period. Demographic data are provided in Table 1. Liver
metastases were metachronous in 106 patients (47.1%). The
median time between primary and CRLM resection was
17.6 months (range: 6.1–73.0 months). In the synchronous
group (n = 119), 19 patients (16.0%) were submitted to sur-
gery based on a liver-first strategy, 20 patients (16.8%) under-
went the resection of both the primary tumour and all liver
metastases during the same operative procedure, and 80
patients (67.2%) underwent a colorectal resection first. In the
latter subgroup (n = 80), colorectal cancer resection was per-
formed first in 21 patients (26.3%) because of emergency
[intestinal obstruction (n = 15), perforation (n = 1) and
abdominal pain (n =5)]. Thirteen patients (16.3%) underwent
two-stage liver resection including primary tumour resection
and clearance of the liver left lobe. In 12 patients (15.0%) liver
metastases was diagnosed within 6 months of the primary malig-
nancy resection, and 34 patients (42.5%) were referred to the
present tertiary referral centre after colorectal tumour surgery.
Overall, repeat hepatectomy was performed in 32 cases
(14.2%). One patient underwent three resections.
Therapeutic modalities of liver metastases
Preoperative chemotherapy
A total of 145 patients (64.4%) underwent preoperative
chemotherapy. Sixty patients (41.4%) had resectable disease
and were treated using the FOLFOX 4 protocol as described by
the European Organization for Research and Treatment of
Cancer (EORTC).14 A total of 85 patients (58.6%) were identi-
fied as having potentially resectable liver metastases and under-
went induction chemotherapy, with antiangiogenic or targeted
therapies. A mean of 7.4 cycles of preoperative chemotherapy
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were administrated (5.6 cycles in the FOLFOX 4 group and 9.1
cycles in the induction chemotherapy group).
Eighty patients (35.6%) did not benefit from preoperative
chemotherapy. Nineteen (23.8%) of these had a medical con-
traindication. Twenty-six patients (32.5%) presented with small
lesions (i.e. <1 cm) which were at risk for disappearance on
chemotherapy and were resected first. Twenty-four patients
(30.0%) were diagnosed with liver metastases within 6 months
of the cessation of previous chemotherapy, and 11 patients
(13.8%) were operated before the wider introduction of peri-
operative chemotherapy protocols (i.e. before 2008).
Radiological studies
All patients underwent CT before surgery. Liver MRI was avail-
able for 202 patients (89.8%), and was performed in the pres-
ent centre in 178 patients. All preoperative assessments were
reviewed at the colorectal and hepatobiliary MDT meeting.
Twenty-three patients (10.3%) did not undergo liver MRI
before surgery because of medical contraindications (e.g. claus-
trophobia, an implanted pacemaker).
The results of radiological studies were available for 217
patients. In eight cases the latest radiological studies had to be
reinterpreted. The mean number of lesions counted per patient
was 2.9 (range: 1–17). The median number of metastases was
two (range: 1–4). These tumours were solitary in 81 patients
(36.0%), located in the left lobe in 42 patients (18.7%), in the
right lobe in 85 patients (37.8%) and were bilobar in 98
patients (43.6%). The mean number of tumours was 4.6
(range: 2–17) in patients with bilobar disease and 1.7 (range:
1–8) in patients with unilobar disease (P < 0.0001). The med-
ian time between preoperative MRI and surgical resection was
36 days (range: 1–266 days). Fifty-nine patients (26.2%)
underwent an additional abdominal CT scan performed on the
day before surgery.
Surgery and IOUS
All operated patients underwent liver resection with curative
intent, except in one instance as a result of peritoneal carcino-
matosis. Five patients in the two-stage liver resection group
did not undergo the second-stage procedure because of liver
disease progression and were therefore excluded. Of the
remaining 219 patients for whom data were analysed, liver
resection was performed using an open-surgery approach in
205 (93.6%) and a laparoscopic approach in 14 patients
(6.3%). Data on the type of resection are provided in Table 2.
Resections were conducted without IOUS in 41 procedures
(18.7%). In 27 of these patients, malignancies were easily
palpable and were identified using recent MRI and CT scans.
In the remaining 14 operations, laparoscopy was employed
without IOUS. During these procedures, intraoperative palpa-
tion identified two new lesions that were resected, but final
histology showed them to have been benign.
Intraoperative US scans were achieved in 178 patients
(81.3%), of whom 163 (91.6%) underwent both preoperative
liver MRI and CT. The remaining 15 patients underwent only
Table 1 Patient and disease characteristics in 225 patients
scheduled for hepatectomy for colorectal liver metastases
Variables Value
Gender, n (%)
Male 141 (62.7)
Female 84 (37.3)
Age, years, mean  SD 62.4  11.6
Age <65 years, n (%) 131 (58.2)
Age ≥65 years, n (%) 94 (41.8)
Body mass index, kg/m2, mean  SD 27.0  4.7
ASA class, n (%)
1 16 (7.1)
2 127 (56.4)
3 82 (36.4)
4 0
Primary tumour location, n (%)
Right colon 49 (21.8)
Transverse colon 7 (3.1)
Left colon 106 (47.1)
Rectum 63 (28.0)
Liver metastases at diagnosis, n (%)
Synchronous 119 (52.9)
Metachronous 106 (47.1)
Distribution of liver metastases, n (%)
Left liver 42 (18.7)
Right liver 85 (37.8)
Bilobar 98 (43.6)
ASA, American Society of Anesthesiologists; SD, standard deviation.
Table 2 Operative data in 225 patients scheduled for hepatectomy
for colorectal liver metastases
Variables n (%)
Major hepatectomy 98 (43.6)
Two-stage hepatectomy 28 (12.4)
Right hepatectomy 35 (15.6)
Extended right hepatectomy 22 (9.8)
Left hepatectomy 13 (5.8)
Minor hepatectomy 121 (53.8)
Left lateral sectionectomy 24 (10.7)
Segmentectomy 42 (18.7)
Wedge resection 55 (24.4)
No resection 1 (0.4)
Disrupted two-stage hepatectomy 5 (2.2)
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preoperative CT. Intraoperative exploration found 20 tumours
that had not been previously described on radiological reports
in 18 patients (8.2%). Fourteen (77.8%) of these patients were
known to have bilobar disease and four patients had unilobar
disease. All of these patients underwent an additional proce-
dure (i.e. not planned preoperatively). However, in 15 patients,
tumours were found during liver inspection or palpation. Of
20 unplanned resected tumours, histology showed only 12 to
be metastatic and eight to be benign. Intraoperative US
allowed the diagnosis of lesions that had not been identified by
preoperative imaging or intraoperative visual and manual
palpation in only three patients (1.4%) and final histology
demonstrated benign disease in two of them (Fig. 1).
Postoperative course
The mean hospital stay was 11.8 days (range: 3–52 days).
Mortality at 90 days was 0.8%. Both of the deceased patients
had undergone major hepatectomy after preoperative chemo-
therapy. One developed acute portal vein thrombosis and liver
failure, and the other developed multi-organ failure with pleural
effusion, cerebral haemorrhage and liver failure on a background
of steatosis.
Forty patients (18.3%) developed a major complication (i.e.
Clavien–Dindo Grade IIIa or higher15) in the postoperative
course (Table 3).
Postoperative chemotherapy was administered in 145
(66.2%) patients. During follow-up (mean: 19.5 months),
recurrence was noted in 119 patients (54.3%), in 77 (64.7%)
of whom recurrence affected the liver only. The mean time
between surgery and recurrence in the liver was 37 weeks
(range: 1–232 weeks), including in 27 patients (12.3%) in
whom early liver recurrence (Fig. 2) was recorded within
6 months after surgery. Among the 77 patients with intrahe-
patic recurrence, only 33 underwent second or third hepatecto-
mies with curative intent.
Predictors of intraoperative detection of new nodules
On univariate analysis, the mean numbers of lesions described
on preoperative imaging differed significantly between patients
in whom lesions were and were not discovered intraoperatively.
Patients in whom lesions were discovered intraoperatively had
more nodules on preoperative imaging than patients in whom
225 patients
219 hepatectomy
No IOUS
41 Patients (18.7%)
Additional metastases
12/20
Additional metastases
0/2
IOUS
178 Patients (81.3%)
New nodules
Inspection and
palpation: n = 2
New nodules
Inspection and
palpation: n = 17
8 benign lesions
New nodules: IOUS group
    - n = 20
    - 18 patients
New nodules
 IOUS alone: n = 3
6 Exclusions:
   - 1 peritoneal carcinomatosis
   - 5 tumoral progression 
Figure 1 Study flow chart showing intraoperative findings in 225
patients scheduled for hepatectomy for colorectal liver
metastases. IOUS, intraoperative ultrasonography
Table 3 Morbidity: complications of Clavien–Dindo Grade III or
higher in 219 patients submitted to hepatectomy for colorectal
liver metastases (n = 40 patients, 18.3%)
Complications n (%)
Biliary fistula 5 (2.2)
Abdominal fluid collection 12 (5.5)
Intra-abdominal bleeding 2 (0.9)
Portal vein thrombosis 1 (0.5)
Pleural effusion 21 (9.6)
Pneumonia 4 (1.8)
Cardiac failure 4 (1.8)
Heart rhythm disorder 6 (2.7)
Renal failure 9 (4.1)
Liver insufficiency 6 (2.7)
Myocardial infarction 1 (0.5)
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Figure 2 Intrahepatic recurrence-free survival in 219 patients
submitted to hepatectomy for colorectal liver metastases
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no new lesions were discovered intraoperatively (3.5 versus 2.8
lesions; P = 0.022). Fourteen of 98 patients (14.3%) with bilobar
disease presented an additional lesion compared with only four
of 127 patients (3.1%) with unilobar disease (P = 0.002). Sex,
BMI, age at diagnosis, preoperative chemotherapy administra-
tion, synchronous or metachronous status, and time between
preoperative MRI and surgery did not differ statistically between
patients with and without additional liver nodules, respectively.
Discussion
The major finding of this study is that liver IOUS affects the
surgical strategy in only 1.4% of patients when an accurate
multidisciplinary preoperative evaluation of the liver is per-
formed using liver MRI and abdominal CT. Intraoperative US
is safe and inexpensive, allows for the detection and character-
ization of nodules, locates vascular and biliary structures and
makes the execution of anatomic or non-anatomic liver resec-
tion more precise. It has been widely used for years, and has
been considered as the reference standard in the identification
of liver metastases and to have a significant impact on decision
making in liver resection.16,17 Changes in preoperatively
planned surgical procedures attributable to findings on IOUS
have been reported to affect 2.7–73.0% of operations.5,10,16–18
In the present authors’ experience, IOUS has been used
mainly to check for new lesions in the future remnant liver in
patients in whom anatomical resection is planned, whereas
other groups have previously studied the sensitivity of liver
IOUS in the detection of liver metastases10 and primary
lesions17,19 and have therefore screened the whole surface of
the liver. However, the number of lesions in the portion of the
liver scheduled for resection was not always mentioned and the
liver was not always screened during the operation.
The present results are equivalent to those of Tamandl
et al.,11 who concluded that with adequate preoperative staging
and a multidisciplinary approach, the likelihood of detecting
additional lesions during surgery is very low, despite extensive
treatment with preoperative chemotherapy. In 8.2% of
patients, intraoperatively discovered lesions were subcapsular
and measured <1 cm in diameter. Wagnetz et al.12 found a
change in surgical management attributable to IOUS in only
2.7% of cases. If there is doubt in preoperative cross-sectional
imaging, IOUS may be useful and should be employed to map
intraparenchymal structures to improve the safety of the resec-
tion. In the present authors’ experience, the yield of new
lesions detected by IOUS is very low, but IOUS must be con-
sidered part and parcel of modern liver surgery. Intraoperative
US is probably not required to detect peripheral lesions during
surgery, but it represents the only way of detecting deeply
located lesions and of assessing the proximity of vessels and
bile ducts to allow safe resection. Hata et al.5 believed that
visual inspection, palpation and IOUS were indispensable in
the detection of new nodules. In 254 patients selected for
surgery, 65 (25.6%) were found to have new lesions on intra-
operative exploration and scheduled hepatectomy was altered
in 47 (18.5%) patients. Most patients underwent an additional
tumourectomy, but liver MRI was not performed routinely in
this series. Ferrero et al.10 noted intraoperative changes in
26.4% of 140 patients, but only 51.0% of their patients under-
went preoperative liver MRI.
Various authors have focused on preoperative CT in the
past,19,20 but the technique is nowadays more accurate with
the use of multi-phase helical CT. Furthermore, MRI has been
revolutionized by the addition of liver contrast agents and dif-
fusion sequences. In fatty liver associated with neoadjuvant
chemotherapy, Kulemann et al.21 found the sensitivity of MRI
to be about 88% and that of abdominal CT to be 65%, thereby
demonstrating a statistically significant difference in small
lesions. In a meta-analysis, van Kessel et al.22 described sensi-
tivity of 84.5% (range: 69.7–94.0%) for MRI and 69.9% (range:
65.6–73.2%) for abdominal CT. Liver MRI seems to be the
best imaging modality for preoperative assessment of patients
with CRLM. According to Niekel et al.,23, the mean sensitivi-
ties of CT, liver MRI and FDG-PET on a per-patient basis
were 81.2%, 93.4% and 94.2%, respectively; the sensitivity of
CT was significantly lower than that of FDG-PET (P = 0.025),
whereas specificity was comparable. A number of studies have
shown that the accuracy of preoperative imaging decreases for
liver lesions of <15 mm in size.24 Most of the newly described
lesions in the present patients were millimetric and required
only a single further wedge resection.
Previous studies have described factors predictive of the intra-
operative discovery of CRLM. Synchronous and bilobar metasta-
ses numbering four or more, BMI of >30 kg/m2 and time
between last imaging and surgery of >18 days were considered
predictive of the detection of new nodules by IOUS.10,24 In the
present study, factors associated with the detection of additional
lesions by IOUS included the mean number of tumours per
patient and the bilobar aspect of the disease. In other words,
additional lesions are probably discovered intraoperatively more
often in patients with more aggressive disease.
The results of intraoperative contrast-enhanced US
(CE-IOUS) are controversial.25 Schulz et al.26 found 31 addi-
tional metastases over 369 tumors (8%) by using intraoperative
CE-IOUS. These findings were not confirmed by Ferrero et al.10
or Torzilli.27 The current authors have no experience of
CE-IOUS in the study department, but its advantage is ques-
tionable.
This study has some limitations. Although data were
collected prospectively, the analysis remains retrospective.
Substantial numbers of patients were referred to the present
centre after receiving initial care in other hospitals. Most of
these had not undergone pretreatment MRI, but had received
chemotherapy before referral. Intraoperative US focused only
on the future remnant liver and on the liver structure to guide
resection, but did not check for numbers of lesions in the
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portion of the liver scheduled for resection. The present
authors believe that all patients will benefit from preoperative
CT and MRI during the 4 weeks prior to surgery.
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